Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$19.63 USD
-0.31 (-1.55%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $19.61 -0.02 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 1 - 20 ( 122 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 6124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 52124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 51124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 5124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 42124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
DSMB Greenlights Continuing Simufilam Phase 3 Trials; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 41124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 4124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 32124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 31624
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
FY23 Results: Phase 3 Studies Outperforming; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 3124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 22124
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 21224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 12224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 1224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 12223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 111123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Enrollment of 1,929 Should Leave No Doubt; There?s High Interest in Simufilam; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 11123
Provider: Stock Traders Daily
Analyst: Research Department